t - ICON plc

7:30 Coffee and registrationHOW HAVE ORGANISATIONSTRANSFORMED TO SURVIVE THE STORM?8:50 Opening remarks from the ChairRichard Barker,Director General,Association of the British PharmaceuticalIndustry (ABPI)9:00 A Comprehensive Review of CRO Activity in 2010 Which parts of the CRO industry has seen a drop in revenue over the pasttwelve months? To what degree has pharma consolidation affected CRO revenues in 2010? An examination of private equity activity in CROs Critically assessing the service provider pipeline in 2011 How did overall R&D spend change in 2010? What’s the market outlook for niche CROs in 2011? Which phases have created the highest volume of business for CROs? Where has growth occurred in RFP activity?Gareth Down Ph.D.,Head of European Healthcare,William Blair International9:30 Surviving Difficult Times: How Much Has the RecessionReally Affected Clinical Outsourcing and how does theindustry need to change? Has there been a reduction in internal fixed costs, an overall cut in R & Dinvestment, or both? Have there been job losses or job shifts from pharma to CROs? In what ways have the financial pressures created opportunities for pharma? What are the other drivers for change in the way we run clinical trials andhow much is actually changing? The trend towards emerging markets – is the industry really prepared for this? How did the recession affect the length of the studies across the industry? To what extent is there a paradigm shift in the way partners now share risk? What are the strategies that Pharma needs to employ to survive? How have the small biotechs and virtuals fared during the recession? What is coming out as the light at the end of the tunnel? Impact on changes to payment terms and contract budget models (i.e. fixed,unit based, milestone-types etc)Dalvir Gill,President, Late Stage Development,PharmaNetMAXIMISING RESOURCESTHROUGH FLEXIBLECLINICAL OUTSOURCINGChair: Simon Higginbotham, Senior VicePresident and Chief Marketing Officer, Kendle14.50 Getting the most out of Functional serviceprovider model How do they manage resources? How do they develop transparency? Challenges around developing and retracting How do you provide overall business continuity? How do you manage talent with the sponsor team andprovider team? What are the lead times required for getting the bestpeople on your project? How do you manage the contracts? In particular ifseveral vendor-deliverables are linked to each other?Linda Christmas, Executive Vice President,Resourcing Solutions, ChilternDr Chris Eastwood, Senior Regional AreaManager, GB R&D Europe, Allergan UK15.25 Examining the Practicalities andAdvantages of an "In-Sourced" Model How can an in-sourced model assist in proactivelymanaging resources? What project types lendthemselves best to in-sourcing? What does in-sourcing offer beyond 'renting alab coat'? What is the reality of 'in-sourced' reporting structures? Firsthand examples of building Quality into thein-sourced model, e.g. identification of trainingneeds and proactive issue resolutionDiane Lewis, PhD, Senior Director, CoSource,Clinical Development Services, Covance“Still the best Outsourcing and Networking event”CONFERENCE DAY ONE: Wednesday 17th November 201010:00 Keynote Address: How has the world been changed bythe recession? What is the current landscape for globalisation? Where next for potential markets? What are the implications for the big business? Will Europe be the loser in a world divided between Asia and America? How did the emerging economies fare during the recession and what is theexpected growth for the next five years? Long-term effect on the global and local economy as a result of naturaldisasters (island volcano, tsunami)Quentin Peel,Associate Editor,The Financial Times10:40 Morning coffee and exhibition - sponsored by S-Clinica11:20 Creating winning strategic partnerships:ClinTec – Merck Sharp & Dohme Global experience ClinTec expansion and growth into 17 new countries in 2009 Aligning the global insourcing & outsourcing model dependant on geography Successful ClinTec global delivery through the MSD/Schering mergerStefania Sordoni,Global Procurement Country Lead, EMEA,MSDandDr Rabinder Buttar,President & CEO,ClinTec International Group11:50 Keynote panel discussion: Getting true strategic value fromclinical partnerships – how have sponsors and providersresponded to increased cost pressures?Never before has clinical development relied so heavily on strong, strategicpartnerships. Low R&D productivity, rising costs, and the looming patent clifffor blockbuster drugs have resulted in consolidation and staff reductions acrossthe industry. All pharmaceutical and biotech companies are looking at radicalways to reduce fixed costs, while still delivering high quality trials on time andon budget. This keynote panel will discuss: Reviewing recent consolidation activity within pharma – is the industryresponding to cost-pressure or actually changing its model? What does consolidation actually mean for the service provider market? What innovative approaches are sponsors and CROs taking to deliver drugsin a more efficient way? What does it mean to be a well-managed service provider in 2010 –how to bear through the storm What will clinical outsourcing look like five years from now (and how dopartnerships need to change to achieve this)?Quentin Peel,Associate Editor,The Financial TimesWarren Myers,Formerly Head ofR&D Strategic Sourcing,AmgenVasco M. Grilo,Vice-President GlobalPharmaceutical R&DSourcing (GPS),Johnson & JohnsonPharmaceutical Research& Development, L. L. C.12:20 Agile Project Management and the Battle of Britain;the lessons for Clinical Development Partnerships Identifying the demands of a highly complex projects If a clinical project were the Battle of Britain, who are the fighter pilots andwho are the air traffic controllers? The crucial importance of leadership and trust in outsourced projectsStephen Carver,Project Management Specialist and Lecturer,Cranfield University, One of Europe's top business schoolsSTREAM A STREAM B STREAM C STREAM DIMPROVING PROJECTMANAGEMENT IN YOURCLINICAL PARTNERSHIPSChair: Susan C. Stansfield, Ph.D, ExecutiveVice President, Product Registration – Europe,Africa and Asia-Pacific, PRAPARTNERING SOLUTIONSFOR SMALL PHARMAAND BIOTECHChair: Daniel Spasic, Chief Executive Officer,TFS14.50 Interactive session: refreshing the way that wemeasure our service providers' performance How important is quality in the time-cost qualitymatrix? Is there a better way of measuring this matrix? Why timelines are not the most important way ofmeasuring a CRO Measuring a CRO on quality of information ratherthan cost Engaging rather than managing stakeholders todeliver quality What makes a quality supplier? Taking out the guessworkRoger Joby, Director, 1to1to1“A good insight on the subject even forthe ones not familiar with the field”Director of Biostatistics & Programming,Nerviano Medical Sciences15.25 Extended Project Management ClinicThis is your opportunity to ask the panel about yourspecific Project Management issues or just to find outwhat you didn’t know about project management.The panel of Stephen Carver, Keith Rodgers and RogerJoby has been chosen to give the delegates the widestpossible experience to tap into.Stephen is and experienced practitioner in severaldifferent industries including pharmaceuticals,petrochemicals, banking and a well respected academic.Both Keith and Roger have a wealth of experience in clinicalresearch, Keith predominantly in Pharma and Rogerpredominantly in CROs. So we have covered all of the bases.We hope that the agenda will be driven by you we dohave a contingency plan in the form of a vox pop survey.Ipsen Ltd“Good conferences andnetworking opportunities”Account Manger, Eurofins Medinet13:10 - 14:50Lunch and exhibition - sponsored by Esoterix15:20-15:25 5 minute change over14.50 Biotech Keynote: Learning to let go and relyon your providers: what Can Large PharmaLearn from Biotech about outsourcing? Examining the hard metrics of Biotech’s external costs How do Biotechs overcome the constraints of externalclinical development? How do Biotechs develop process-driven qualityplatforms on limited resources? What are the elements of large pharma that make themuncompetitive? How do biotechs remain hands-off whilst maintainingultimate responsibility? What measurements can pharma and CROs put in placeto let go of micro management? Defining responsibilities and accountability to the CRO:how do biotechs do this successfully?Fredrik Sjovall, Managing Director, Lipopeptide AB15.25 Clinical Development In A New TherapeuticArea: The Challenges for Small Companies Renovo background and history The impact of scarring in the skin Clinical development challenges of new therapeutic areas Outsourcing strategy: In house expertise versusoutsourced resource CRO selection: Selection process, selection criteria,deciding factors- Contractor management: Quality- Contractor management: Financial- Contractor management: Timescale- Conclusions and recommendationsMark Cooper, Senior VP, Clinical Operations,RenovoMatthias R. Evers,Principal, McKinsey& CompanyJane Clarke,Formerly AssistantVice President,Clinical DevelopmentSupport, WyethDave Gillogly,Global Head, ClinicalContracting & CategoryManagement, NovartisPharmaceuticalsCorporationINNOVATIVE APPROACHESTO STRATEGIC CLINICALOUTSOURCINGChair: Janet L. Brennan, Executive Vice President& Chief International Affairs Officer, RPS14.50 Moving Beyond a Tactical FSP/InsourcingModel and Truly Sharing the Skin in theGame: Examining True Risk/RewardModels in Integrated (Embedded)Outsourced PartnershipsThe industry has realized that while cost-effective,FSP/Insourcing/Resourcing Solutions are often tacticalin nature and limited in providing long-term strategicvalue. This session characterizes robust integrated(embedded) partnerships designed to not only reducecosts but more importantly to improve quality andexpedite drug development processes. This operatingmodel involves engagements that are long-term, spanentire development pipelines, involve strong governanceoversight, and require significant trust on both thesponsor and partner’s end. This session will concentrateon how sponsor companies, in partnership withproviders, are able to employ true risk/reward modelsthat yield long-term value tied to measurable dimensionsof quality, innovation, speed, productivity, and cost.Biopharmaceutical Industry panelists will discuss: Identifying key drivers and elements of a shared riskmodel that are tied to critical corporate objectives Developing risk/reward models that bring the greatestvalue across the dimensions of quality, innovation,speed, productivity, and cost Empowering teams to implement risk/reward strategy Process of continuously aligning risk/reward modelswith evolving corporate strategy and objectivesModerator: Samir Shah, Vice President, RPS, IncPanelists include:Jennifer Goodfellow, Senior Director & GlobalHead, Clinical Outsourcing, sanofi pasteur15.25 Successful Approaches to Partnering inpost-marketing Studies How to work in partnership to meet both regulatoryrequirements and commercial needs How to work in partnership in the development andexecution of patient registries Exploring the vendor landscape in Phase IV Connecting your Phase IV trial to potential marketsthrough health economics and outcomes research What is different operationally in a Phase IV partnership? Closing the gap between Clinical Development andSales/MarketingJeff Trotter, Executive Vice President, Phase IVDevelopment, PharmaNett: +44 (0) 20 7017 7481 f: +44 (0) 20 7017 7823 w: www.ct-partnerships.com